Co-Authors
This is a "connection" page, showing publications co-authored by Fengcai Zhu and Jing-Xin Li.
Connection Strength
2.328
-
Adjuvantation helps to optimise COVID-19 vaccine candidate. Lancet Infect Dis. 2021 07; 21(7):891-893.
Score: 0.933
-
Coronavirus disease 2019 vaccines: landscape of global studies and potential risks. Chin Med J (Engl). 2021 Aug 02; 134(17):2037-2044.
Score: 0.240
-
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021 07 15; 6(1):271.
Score: 0.239
-
Next Steps for Efficacy Evaluation in Clinical Trials of COVID-19 Vaccines. Engineering (Beijing). 2021 Jul; 7(7):903-907.
Score: 0.237
-
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl). 2021 Apr 28; 134(11):1289-1298.
Score: 0.236
-
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 08 15; 396(10249):479-488.
Score: 0.223
-
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 06 13; 395(10240):1845-1854.
Score: 0.221